﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2023v5.1">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2024-09-11T15:31:44-05:00</ReturnTs>
    <TaxPeriodEndDt>2023-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>390747409</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>REILLY PENNER &amp; BENTON LLP</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>1233 NORTH MAYFAIR RD SUITE 302</AddressLine1Txt>
        <CityNm>MILWAUKEE</CityNm>
        <StateAbbreviationCd>WI</StateAbbreviationCd>
        <ZIPCd>532263255</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2023-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>222628153</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>INTERNATIONAL FOUNDATION FOR ETHICAL</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>RESEARCH INC</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>INTE</BusinessNameControlTxt>
      <PhoneNum>3124276025</PhoneNum>
      <USAddress>
        <AddressLine1Txt>444 NORTH WELLS STREET 406</AddressLine1Txt>
        <CityNm>CHICAGO</CityNm>
        <StateAbbreviationCd>IL</StateAbbreviationCd>
        <ZIPCd>606544594</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>KENNETH KANDARAS</PersonNm>
      <PersonTitleTxt>PRESIDENT</PersonTitleTxt>
      <PhoneNum>3124276025</PhoneNum>
      <SignatureDt>2024-09-10</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>1</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>KATHERINE HOFFMAN</PreparerPersonNm>
      <PTIN>P01458876</PTIN>
      <PhoneNum>4142717800</PhoneNum>
    </PreparerPersonGrp>
    <TaxYr>2023</TaxYr>
    <BuildTS>2024-08-08 14:25:15Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="10">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <PrincipalOfficerNm>KENNETH KANDARAS</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>444 NORTH WELLS STREET 406</AddressLine1Txt>
        <CityNm>CHICAGO</CityNm>
        <StateAbbreviationCd>IL</StateAbbreviationCd>
        <ZIPCd>606544594</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>331116</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>0</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>IFER.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1985</FormationYr>
      <LegalDomicileStateCd>IL</LegalDomicileStateCd>
      <ActivityOrMissionDesc>TO ADVANCE THE DEVELOPMENT AND IMPLEMENTATION OF HUMAN-RELEVANT, NON-ANIMAL ALTERNATIVES IN RESEARCH, TESTING AND EDUCATION.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>6</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>6</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <TotalVolunteersCnt>10</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>276170</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>202520</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>11443</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>14914</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>0</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>0</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>287613</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>217434</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>93000</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>142500</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>0</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>0</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>0</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>31028</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>46681</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>124028</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>189181</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>163585</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>28253</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>870064</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>1018772</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>0</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>30000</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>870064</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>988772</NetAssetsOrFundBalancesEOYAmt>
      <MissionDesc>TO ADVANCE THE DEVELOPMENT AND IMPLEMENTATION OF HUMAN-RELEVANT, NON-ANIMAL ALTERNATIVES IN RESEARCH, TESTING AND EDUCATION.</MissionDesc>
      <SignificantNewProgramSrvcInd>0</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>0</SignificantChangeInd>
      <ExpenseAmt>170078</ExpenseAmt>
      <GrantAmt>142500</GrantAmt>
      <Desc>INTERNATIONAL FOUNDATION FOR ETHICAL RESEARCH, INC. HAS FUNDED SEVEN MEDICAL RESEACH PROJECTS THAT UTILIZE HUMAN-RELEVANT, NON-ANIMAL ALTERNATIVES AS THEIR TEST MODELS. THE PROJECTS MAY HELP COUNTLESS PATIENTS WITHOUT HARMING ANIMALS.</Desc>
      <TotalProgramServiceExpensesAmt>170078</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="RetDoc1039100001">1</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="RetDoc1234500001">1</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>0</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>0</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd>0</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="RetDoc1040000001">0</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="RetDoc1040000001">0</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="RetDoc1040000001">0</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="RetDoc1040000001">0</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>0</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="RetDoc1040000001">0</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="RetDoc1040000001">0</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="RetDoc1040000001">0</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="RetDoc1040000001">0</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="RetDoc1040000001">0</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="RetDoc1040000001">1</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">0</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">0</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>0</SchoolOperatingInd>
      <ForeignOfficeInd>0</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="RetDoc1040500001">1</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="RetDoc1040500001">1</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="RetDoc1040500001">0</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>0</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>0</FundraisingActivitiesInd>
      <GamingActivitiesInd>0</GamingActivitiesInd>
      <OperateHospitalInd>0</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="RetDoc1041900001">0</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="RetDoc1042400001">1</ScheduleJRequiredInd>
      <TaxExemptBondsInd>0</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd referenceDocumentId="RetDoc1042800001">0</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd referenceDocumentId="RetDoc1042800001">0</PYExcessBenefitTransInd>
      <LoanOutstandingInd referenceDocumentId="RetDoc1042800001">0</LoanOutstandingInd>
      <GrantToRelatedPersonInd referenceDocumentId="RetDoc1042800001">0</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd referenceDocumentId="RetDoc1042800001">0</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd referenceDocumentId="RetDoc1042800001">1</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>0</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd>0</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>0</DeductibleArtContributionInd>
      <TerminateOperationsInd>0</TerminateOperationsInd>
      <PartialLiquidationInd>0</PartialLiquidationInd>
      <DisregardedEntityInd referenceDocumentId="RetDoc1043400001">0</DisregardedEntityInd>
      <RelatedEntityInd referenceDocumentId="RetDoc1043400001">1</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>0</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd referenceDocumentId="RetDoc1043400001">0</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd referenceDocumentId="RetDoc1043400001">0</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>1</ScheduleORequiredInd>
      <IRPDocumentCnt>0</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <EmployeeCnt>0</EmployeeCnt>
      <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>0</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>0</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>0</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>0</QuidProQuoContributionsInd>
      <Form8282PropertyDisposedOfInd>0</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>0</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>0</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>6</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>6</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>0</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>0</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>0</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>0</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>0</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>0</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>0</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>1</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>1</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>0</OfficerMailingAddressInd>
      <LocalChaptersInd>0</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>1</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>1</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>1</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>1</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>1</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>1</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>0</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>0</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>0</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <OtherWebsiteInd>X</OtherWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <BusinessName>
          <BusinessNameLine1Txt>KENNETH KANDARAS</BusinessNameLine1Txt>
        </BusinessName>
        <PhoneNum>3124276025</PhoneNum>
        <USAddress>
          <AddressLine1Txt>444 NORTH WELLS STREET 406</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>606544594</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>KENNETH KANDARAS</PersonNm>
        <TitleTxt>PRESIDENT</TitleTxt>
        <AverageHoursPerWeekRt>5.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>40.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>166156</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOHN H SCHEID JR</PersonNm>
        <TitleTxt>TREASURER/SECRETARY</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARY MARGARET CUNNIFF</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SYLVIA O DECKER</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>THOMAS S MOORE</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>PAMELA OSENKOWSKI PH D</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>5.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>0</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>166156</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>0</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>0</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>0</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>1</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>0</CompensationFromOtherSrcsInd>
      <CntrctRcvdGreaterThan100KCnt>0</CntrctRcvdGreaterThan100KCnt>
      <AllOtherContributionsAmt>202520</AllOtherContributionsAmt>
      <TotalContributionsAmt>202520</TotalContributionsAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>19086</TotalRevenueColumnAmt>
        <ExclusionAmt>19086</ExclusionAmt>
      </InvestmentIncomeGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>109510</SecuritiesAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>113682</SecuritiesAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>-4172</SecuritiesAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>-4172</TotalRevenueColumnAmt>
        <ExclusionAmt>-4172</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>217434</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>14914</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>130000</TotalAmt>
        <ProgramServicesAmt>130000</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>12500</TotalAmt>
        <ProgramServicesAmt>12500</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>18534</TotalAmt>
        <ProgramServicesAmt>18534</ProgramServicesAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>6800</TotalAmt>
        <ManagementAndGeneralAmt>6800</ManagementAndGeneralAmt>
      </FeesForServicesAccountingGrp>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>5930</TotalAmt>
        <ManagementAndGeneralAmt>5930</ManagementAndGeneralAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <OfficeExpensesGrp>
        <TotalAmt>1294</TotalAmt>
        <ManagementAndGeneralAmt>1294</ManagementAndGeneralAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>596</TotalAmt>
        <ProgramServicesAmt>447</ProgramServicesAmt>
        <ManagementAndGeneralAmt>149</ManagementAndGeneralAmt>
      </InformationTechnologyGrp>
      <TravelGrp>
        <TotalAmt>3597</TotalAmt>
        <ProgramServicesAmt>3597</ProgramServicesAmt>
      </TravelGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>2500</TotalAmt>
        <ProgramServicesAmt>2500</ProgramServicesAmt>
      </ConferencesMeetingsGrp>
      <OtherExpensesGrp>
        <Desc>STATE FILING FEES</Desc>
        <TotalAmt>4171</TotalAmt>
        <ManagementAndGeneralAmt>4171</ManagementAndGeneralAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>SPONSORSHIPS</Desc>
        <TotalAmt>2500</TotalAmt>
        <ProgramServicesAmt>2500</ProgramServicesAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>FOREIGN TAXES</Desc>
        <TotalAmt>759</TotalAmt>
        <ManagementAndGeneralAmt>759</ManagementAndGeneralAmt>
      </OtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>189181</TotalAmt>
        <ProgramServicesAmt>170078</ProgramServicesAmt>
        <ManagementAndGeneralAmt>19103</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>218523</BOYAmt>
        <EOYAmt>39305</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <EOYAmt>216340</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>651541</BOYAmt>
        <EOYAmt>756230</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>6897</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>870064</BOYAmt>
        <EOYAmt>1018772</EOYAmt>
      </TotalAssetsGrp>
      <GrantsPayableGrp>
        <EOYAmt>30000</EOYAmt>
      </GrantsPayableGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>30000</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>870064</BOYAmt>
        <EOYAmt>988772</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>870064</BOYAmt>
        <EOYAmt>988772</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>870064</BOYAmt>
        <EOYAmt>1018772</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>28253</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>90455</NetUnrlzdGainsLossesInvstAmt>
      <OtherChangesInNetAssetsAmt>0</OtherChangesInNetAssetsAmt>
      <InfoInScheduleOPartXIIInd>X</InfoInScheduleOPartXIIInd>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>1</AccountantCompileOrReviewInd>
      <AcctCompileOrReviewBasisGrp>
        <SeparateBasisFinclStmtInd>X</SeparateBasisFinclStmtInd>
      </AcctCompileOrReviewBasisGrp>
      <FSAuditedInd>0</FSAuditedInd>
      <AuditCommitteeInd>1</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>0</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>150000</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>246200</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>291020</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>276170</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>202520</CurrentTaxYearAmt>
        <TotalAmt>1165910</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>150000</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>246200</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>291020</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>276170</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>202520</CurrentTaxYearAmt>
        <TotalAmt>1165910</TotalAmt>
      </TotalCalendarYear170Grp>
      <PublicSupportTotal170Amt>1165910</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>5397</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>7676</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>21604</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>11443</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>14914</CurrentTaxYearAmt>
        <TotalAmt>61034</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus3YearsAmt>4091</CurrentTaxYearMinus3YearsAmt>
        <TotalAmt>4091</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>1231035</TotalSupportAmt>
      <PublicSupportCY170Pct>0.94710</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.13230</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleD documentId="RetDoc1040000001">
      <TotalBookValueLandBuildingsAmt>0</TotalBookValueLandBuildingsAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART X, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>IFER HAS IMPLEMENTED ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH U.S. GAAP. THIS STANDARD PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN AND ALSO PROVIDES GUIDANCE ON VARIOUS RELATED MATTERS SUCH AS DERECOGNIZING, INTEREST, PENALTIES AND DISCLOSURES REQUIRED. MANAGEMENT OF IFER EVALUATES THE UNCERTAIN TAX POSITIONS TAKEN, IF ANY, AND CONSULTS WITH OUTSIDE COUNSEL AS DEEMED NECESSARY. IFER RECOGNIZES INTEREST AND PENALTIES, IF ANY, RELATED TO UNRECOGNIZED TAX LIABILITIES IN INCOME TAX EXPENSE. IN MANAGEMENT'S OPINION, IFER HAS NOT TAKEN ANY UNCERTAIN TAX POSITIONS, AND ACCORDINGLY, HAS NOT REPORTED A CORRESPONDING LIABILITY IN IFER' FINANCIAL STATEMENTS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="RetDoc1040500001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>GRANT MAKING</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>FUNDING SCIENTIFIC RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>12500</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>0</SubtotalEmployeesCnt>
      <ContinuationTotalOfficeCnt>0</ContinuationTotalOfficeCnt>
      <ContinuationTotalEmployeeCnt>0</ContinuationTotalEmployeeCnt>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <SubtotalSpentAmt>12500</SubtotalSpentAmt>
      <ContinuationSpentAmt>0</ContinuationSpentAmt>
      <TotalSpentAmt>12500</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM</RegionTxt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
        <CashGrantAmt>12500</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
      </GrantsToOrgOutsideUSGrp>
      <TransferToForeignCorpInd>0</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>0</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>0</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>0</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>0</ForeignPartnershipInd>
      <BoycottCountriesInd>0</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE F PART II COLUMN D</FormAndLineReferenceDesc>
        <ExplanationTxt>KAROLINSKA INSTITUTE (SWEDEN) THE GRANT WAS GIVEN TO THE KAROLINSKA INSTITUTE TO SUPPORT THE RESEARCH CONDUCTED BY NURIA VILARNAU. MS. VILARNAU'S RESEARCH FOCUSES UPON THE "MECHANISTIC ANALYSES OF HUMAN HEPATOCYTE PLASTICITY." THE GOAL OF MS. VILARNAU'S PROJECT IS TO INVESTIGATE THE REGENERATION OF THE HUMAN LIVER IN VITRO USING A 3D SPHERE CULTURE SYSTEM. CHRONIC LIVER DISEASE IS BECOMING A MAJOR PUBLIC HEALTH CHALLENGE, AND THE MAIN THERAPEUTIC OPTION FOR INDIVIDUALS SUFFERING FROM END-STAGE LIVER DISEASE IS LIVER TRANSPLANTATION. HOWEVER, ANOTHER POTENTIAL THERAPEUTIC APPROACH COULD INVOLVE BOOSTING THE NATURAL REGENERATIVE POTENTIAL OF LIVER CELLS. WHILE THE MAIN MODEL TO STUDY TISSUE REGENERATION HAS RELIED ON RODENTS, THE TRANSLATIONAL IMPACT OF ANIMAL MODELS IS LIMITED DUE TO SPECIES DIFFERENCES. TRADITIONAL TWO-DIMENSIONAL CELL MODELS OF THE HUMAN LIVER HAVE ALSO BEEN INADEQUATE TO STUDY THIS CONDITION. NURIA WILL BE USING A 3D CELL CULTURE SYSTEM THAT ENABLES THE STUDY OF MOLECULAR AND CELLULAR BIOLOGY OF HUMAN ADULT LIVER REGENERATION. SHE WILL INVESTIGATE THE EFFECTS THAT SMALL MOLECULES AND GROWTH FACTORS HAVE ON TRIGGERING HUMAN LIVER CELLS TO GROW AND WILL PERFORM A HIGH-THROUGHPUT GENE EXPRESSION STUDY TO BETTER UNDERSTAND MOLECULAR MECHANISMS IMPORTANT FOR HUMAN LIVER CELL GROWTH.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF TEXAS - DALLAS</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>800 W CAMPBELL ROAD AD15</AddressLine1Txt>
          <CityNm>RICHARDSON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>750803021</ZIPCd>
        </USAddress>
        <RecipientEIN>751305566</RecipientEIN>
        <CashGrantAmt>15000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CORNELL UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>616 THURSTON AVENUE</AddressLine1Txt>
          <CityNm>ITHACA</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>14853</ZIPCd>
        </USAddress>
        <RecipientEIN>150532082</RecipientEIN>
        <CashGrantAmt>15000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>2138 COMPUS DRIVE</AddressLine1Txt>
          <CityNm>DURHAM</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27708</ZIPCd>
        </USAddress>
        <RecipientEIN>562070036</RecipientEIN>
        <CashGrantAmt>15000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3910 KESWICK ROAD SUITE N2100</AddressLine1Txt>
          <CityNm>BALTIMORE</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>21211</ZIPCd>
        </USAddress>
        <RecipientEIN>520595110</RecipientEIN>
        <CashGrantAmt>27500</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>TEXAS A&amp;M UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>400 BIZZELL ST</AddressLine1Txt>
          <CityNm>COLLEGE STATION</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77840</ZIPCd>
        </USAddress>
        <RecipientEIN>746000530</RecipientEIN>
        <CashGrantAmt>27500</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MARYLAND - COLLEGE PARK</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>7901 REGENTS DRIVE</AddressLine1Txt>
          <CityNm>COLLEGE PARK</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>207425025</ZIPCd>
        </USAddress>
        <RecipientEIN>152600203</RecipientEIN>
        <CashGrantAmt>15000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF ROCHESTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>601 ELMWOOD AVENUE</AddressLine1Txt>
          <CityNm>ROCHESTER</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>14626</ZIPCd>
        </USAddress>
        <RecipientEIN>160743209</RecipientEIN>
        <CashGrantAmt>15000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE I PART II COLUMN H</FormAndLineReferenceDesc>
        <ExplanationTxt>CORNELL UNIVERSITY (NEW YORK): THE GRANT WAS GIVEN TO CORNELL UNIVERSITY IN NEW YORK TO SUPPORT THE RESEARCH CONDUCTED BY YANSONG (HARRY) PENG. MR. PENG'S RESEARCH FOCUSES ON "A TISSUE-ENGINEERED PANCREATIC CANCER MODEL FOR DISSECTING THE ROLES OF LYMPHATIC VESSELS IN TUMOR IMMUNITY." THE GOAL OF THIS PROJECT IS TO CREATE A 3D MICROFLUIDIC MODEL FOR DISSECTING THE ROLES OF LYMPHATIC VESSELS IN TUMOR IMMUNITY. PANCREATIC CANCER REMAINS ONE OF THE MOST LETHAL FORMS OF CANCER, WITH LESS THAN 10% OF PATIENTS SURVIVING PAST 5 YEARS. ALTHOUGH THERE IS AN FDA-APPROVED IMMUNOTHERAPY FOR THE DISEASE, FEWER THAN 10% OF PATIENTS RESPOND TO IT, AND QUESTIONS REMAIN ABOUT HOW TO MAKE IMMUNOTHERAPIES MORE EFFECTIVE TREATMENTS. SOME THINK THE RESISTANCE TO IMMUNOTHERAPY IS CAUSED BY DEFECTS IN LYMPHATIC VESSELS WHICH INCREASE THE INTERSTITIAL FLUID PRESSURE IN THE TUMORS AND REDUCE THE ABILITY OF IMMUNE CELLS TO ENTER. IN THIS PROPOSAL, HARRY SEEKS TO CREATE A 3D MICROFLUIDIC MODEL OF VASCULARIZED PANCREATIC CANCER TUMORS IN A DEVICE CONTAINING BLOOD VESSELS, LYMPHATIC VESSELS, AND PANCREATIC CANCER CELLS. HE CAN MIMIC THE INTERSTITIAL FLUID FLOW FOUND IN NORMAL AND TUMOR TISSUES AND EXAMINE THE IMPACT THIS HAS ON INFILTRATION OF IMMUNE CELLS AND RESPONSE TO CANCER IMMUNOTHERAPIES. THE PANCREATIC CANCER ON A CHIP MODEL HAS THE POTENTIAL TO PROVIDE A BETTER UNDERSTANDING OF THE MECHANISM OF IMMUNITY TO IMMUNOTHERAPIES AND TO ALSO SERVE AS A PLATFORM FOR THE SCREENING OF DRUGS FOR THIS CONDITION, WHILE REDUCING THE USE OF ANIMAL MODELS FOR THIS PURPOSE. DUKE UNIVERSITY (NORTH CAROLINA): THE GRANT WAS GIVEN TO DUKE UNIVERSITY TO SUPPORT THE RESEARCH CONDUCTED BY MINGZHI XU, "AN INTEGRATED MICROFLUIDIC SYSTEM WITH ENGINEERED BLOOD VESSEL MIMIC AND SKELETAL MUSCLE TO INVESTIGATE THE RELATION BETWEEN RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS." RHEUMATOID ARTHRITIS (RA) IS A CHRONIC INFLAMMATORY AUTOIMMUNE DISEASE THAT PRIMARILY TARGETS THE JOINTS, BUT ALSO SYSTEMICALLY PROMOTES INFLAMMATION. PATIENTS WITH RA EXPERIENCE MUSCLE WEAKNESS AND ELEVATED INFLAMMATORY CYTOKINES IN THEIR CIRCULATION HAVE INCREASED ATHEROSCLEROSIS, WHICH LEADS TO A HIGHER CARDIOVASCULAR DISEASE (CVD) RISK. SYSTEMIC INFLAMMATION PLAYS AN IMPORTANT ROLE IN ATHEROSCLEROSIS, AND AUTOIMMUNE DISEASES SUCH AS RA ACCELERATE ATHEROSCLEROSIS DUE TO ELEVATED SYSTEMIC INFLAMMATION. ANIMAL MODELS AVAILABLE FOR EITHER ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS HAVE LIMITATIONS, WITH PHENOTYPES THAT ARE COMPLICATED TO PRODUCE AND TAKE A LONG TIME TO DEVELOP. IN THIS PROPOSAL, MINGZHI WILL LINK TISSUE ENGINEERED BLOOD VESSELS (TEBV) AND ENGINEERED SKELETAL MUSCLE MYOBUNDLES MADE WITH HUMAN CELLS TO PRODUCE AN INTEGRATED SYSTEM. THIS SYSTEM WILL BE USED TO INVESTIGATE THE INTERACTION OF BLOOD VESSELS AND MUSCLE IN RA TO IDENTIFY THERAPEUTICS THAT LACK TOXICITY AND DEMONSTRATE EFFICACY IN HUMANS. JOHNS HOPKINS UNIVERSITY: ONE GRANT WAS GIVEN TO JOHNS HOPKINS UNIVERSITY TO SUPPORT THE RESEARCH CONDUCTED BY ALAN KIM. MR. KIM'S RESEARCH FOCUSES UPON "SYNAPTOGENESIS ASSAY FOR DEVELOPMENTAL NEUROTOXICITY TESTING IN A HUMAN 3D BRAIN MODEL." THE GOAL OF MR. KIM'S PROJECT IS TO DEVELOP A QUANTITATIVE IN VITRO MODEL OF SYNAPTOGENESIS, THE FORMATION OF SYNAPSES BETWEEN NEURONS IN THE NERVOUS SYSTEM. SYNAPSES ARE STRUCTURES THAT ALLOW NEURONS TO COMMUNICATE WITH ONE ANOTHER THROUGH CHEMICAL OR ELECTRICAL SIGNALS. SYNAPTOGENESIS IS BELIEVED TO BE DISRUPTED IN AUTISM SPECTRUM DISORDER AND OTHER NEURODEVELOPMENTAL DISORDERS. RATHER THAN USING ANIMAL MODELS TO STUDY DEVELOPMENTAL NEUROTOXICITY, ALAN WILL ENGINEER A HUMAN CELL-BASED MODEL TO STUDY THIS INSTEAD. HE WILL BE WORKING WITH HUMAN INDUCED PLURIPOTENT STEM CELLS AND GENETICALLY EDITING THEM TO EXPRESS DIFFERENT FLUORESCENT TAGS. HE WILL BE DIFFERENTIATING THOSE CELLS INTO NEURONS AND OTHER CELL TYPES OF THE NERVOUS SYSTEM AND GROWING THE CELLS INTO 3D BRAIN ORGANOIDS. THE GENES THAT WERE INSERTED INTO THE CELLS ENABLE THE LABELING OF PRE- AND POST-SYNAPTIC MARKERS WITH DIFFERENT FLUORESCENT TAGS. ALAN WILL USE IMAGE ANALYSIS TO IDENTIFY SYNAPSES BASED ON WHERE THESE MARKERS CO-LOCALIZE AND WILL INVESTIGATE WHETHER CHEMICALS CAN DISRUPT SYNAPTOGENESIS DURING THE DEVELOPMENT OF THE BRAIN ORGANOID MODEL. A SECOND GRANT WAS GIVEN TO JOHNS HOPKINS TO SUPPORT THE RESEARCH CONDUCTED BY DOWLETTE-MARY ALAM EL DIN, "DEVELOPING COGNITION-IN-A-DISH TO INVESTIGATE THE IMPACT OF CHRONIC LOW DOSE DOMOIC ACID EXPOSURE ON NERUONAL DEVELOPMENT AND FUNCTION." DOMOIC ACID (DA) IS A NEUROTOXIN PRODUCED BY ALGAE BLOOMS THAT CAN CONTAMINATE SHELLFISH AND LEAD TO CELLULAR AND STRUCTURAL BRAIN DAMAGE IN EXPOSED HUMANS. ITS PRESENCE IN COASTAL AREAS HAS BECOME MORE FREQUENT DUE TO CLIMATE CHANGE CAUSING AN INCREASE IN THE NUMBER OF HARMFUL ALGAE BLOOMS. MOST STUDIES INVESTIGATING THE ROLE OF DA IN COGNITIVE IMPAIRMENT HAVE BEEN CONDUCTED IN ANIMAL MODELS, BUT DO NOT PROVIDE A BIOLOGICALLY RELEVANT MODEL FOR HUMAN COGNITIVE DEVELOPMENT. IN THIS PROPOSAL, DOWETTE PLANS TO DEVELOP A COGNITION-IN-A-DISH MODEL USING A HUMAN BRAIN ORGANOID TO INVESTIGATE THE EFFECTS OF CHRONIC LOW-DOSE DA EXPOSURE NEURODEVELOPMENTAL EVENTS, FUNCTIONAL NEURAL NETWORK FORMATION, AND COGNITIVE FUNCTIONS. IDENTIFICATION OF THE PATHWAYS THROUGH WHICH DA DISRUPTS COGNITIVE FUNCTION WILL IMPACT HUMAN HEALTH AND SAFETY BY INFORMING REGULATORY GUIDELINES FOR EXPOSURE. UNIVERSITY OF ROCHESTER (NEW YORK): THE GRANT WAS GIVEN TO THE UNIVERSITY OF ROCHESTER TO SUPPORT THE RESEARCH CONDUCTED BY KAIHUA (CHLOE). MS. CHEN'S RESEARCH FOCUSES UPON "IN VITRO STUDIES OF BIOPHYSICAL AND MOLECULAR DETERMINANTS OF THE BLOOD-BRAIN BARRIER DURING SEPSIS AND SYSTEMIC INFLAMMATION." THE GOAL OF THIS PROJECT IS THE IN VITRO STUDY OF BIOPHYSICAL AND MOLECULAR DETERMINATES OF THE BLOOD BARRIER DURING SEPSIS AND SYSTEMIC INFLAMMATION. SEPSIS IS A POTENTIALLY LIFE-THREATENING CONDITION THAT TAKES PLACE WHEN THE BODY RESPONDS TO AN INFECTION BUT DAMAGES ITS OWN TISSUES DURING THE PROCESS. SURVIVORS OF SEVERE SEPSIS OFTEN HAVE COGNITIVE LOSS AND MENTAL PROBLEMS BELIEVED TO BE LINKED TO BRAIN INJURY RESULTING FROM THE DESTRUCTION OF THE BLOOD BRAIN BARRIER AND TRANSPORT OF SEPTIC FACTORS THROUGH BLOOD FLOW. ALTHOUGH MICE ARE COMMONLY USED TO MODEL SEPSIS, THEY DO NOT GIVE RESPONSE PROFILES RESEMBLING THOSE OF HUMANS. IN THIS PROPOSAL, CHLOE PLANS TO DEVELOP A HUMAN CELL-BASED MODEL TO STUDY BRAIN INJURY DURING SEPSIS. HER MODEL WILL INCLUDE THE THREE CELL TYPES COMPRISING THE NEUROVASCULAR UNIT (HUMAN BLOOD VESSEL CELLS, ASTROCYTES, AND PERICYTES) ALONG WITH A MICROFLUIDIC COMPONENT THAT ALLOWS FOR CIRCULATING FLOW WITH A PHYSIOLOGICAL LEVEL OF SHEAR STRESS. SHE WILL USE THE MODEL TO INVESTIGATE HOW INDIVIDUAL CELL TYPES RESPOND TO A SIMULATED SEPTIC 'CYTOKINE STORM AND WILL INVESTIGATE WHETHER SPHINGOSINE 1 PHOSPHATE OFFERS A PROTECTIVE EFFECT. UNIVERSITY OF MARYLAND-COLLEGE PARK (MARYLAND): THE GRANT WAS GIVEN TO THE UNIVERSITY OF MARYLAND-COLLEGE PARK TO SUPPORT THE RESEARCH CONDUCTED BY IAN SMITH, "A SPHEROID ANTIOGENIC VASCULARIZATION MIDROFLUIDIC DEVICE TO REPLACE METASTASIS-BASED MOUSE MODELS." TUMORS COMMONLY CAUSE THE FORMATION OF A NETWORK OF CAPILLARIES AND THE RESULTING INVASION OF CANCERS CELLS INTO BLOOD OR LYMPH VESSELS RESULTS IN THE SPREAD OF CANCER TO OTHER PARTS OF THE BODY. CURRENT IN VITRO MODELS HAVE DIFFICULTIES IN OBSERVING REAL-TIME CELLULAR BEHAVIORS, FAIL TO PROVIDE RELEVANT DATA REGARDING THE MECHANISM UNDERLYING THESE CELLULAR BEHAVIORS, AND OFTEN OVERSIMPLIFY THE COMPLEXITIES FOUND IN VIVO. IN THIS PROPOSAL, IAN PLANS TO VALIDATE A COMPETITIVE IN VITRO MODEL TO REPLACE THE CURRENT IN VIVO MODELS. IAN'S LAB HAS DEVELOPED A SPHEROID ANGIOGENIC VASCULARIZATION MICROFLUIDIC DEVICE (SAVD) THAT INCORPORATES RELEVANT STRUCTURES FOUND IN VIVO, WHILE ALLOWING FOR REAL TIME OBSERVATION ACROSS DIFFERENT IMAGING MODALITIES. HE WILL VALIDATE THE EFFICACY OF THIS DEVICE AND USE IT TO IDENTIFY THE UNDERLYING MECHANISMS OF CANCER CELL INTRAVASATION INTO BLOOD VESSELS AND DEVELOP A TREATMENT REGIME TO MITIGATE THIS PROCESS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE I PART II COLUMN H</FormAndLineReferenceDesc>
        <ExplanationTxt>UNIVERSITY OF TEXAS AT DALLAS (TEXAS): THE GRANT WAS GIVEN TO UNIVERSITY OF TEXAS AT DALLAS TO SUPPORT THE RESEARCH CONDUCTED BY DIVYA SUBRAMANIAN. MS. SUBRAMANIAN' FOCUSES UPON "DEVELOPMENT OF A NOVEL IN-VITRO BIOMIMETIC CORNEAL STROMA USING MICROFLUIDICS TO STUDY CORNEAL WOUND HEALING." THE GOAL OF THIS STUDY IS THE DEVELOPMENT OF A NOVEL IN-VITRO BIOMIMETIC CORNEAL STROMA USING MICROFLUIDICS TO STUDY CORNEAL WOUND HEALING. THE CORNEA IS THE PART OF THE EYE WHICH IS EXPOSED TO THE OUTER ENVIRONMENT AND IS MOST LIKELY TO BECOME DAMAGED DUE TO VARIOUS INSULTS, SO CORNEAL WOUND HEALING IS A SIGNIFICANT CLINICAL PROBLEM AND AN IMPORTANT MEDICAL ISSUE. CORNEAL WOUND HEALING RESEARCH CURRENTLY RELIES HEAVILY ON ANIMAL MODELS, PARTICULARLY RABBITS. HOWEVER, DIFFERENCES BETWEEN RABBIT AND HUMAN CORNEAS MAKE EXTRAPOLATION OF DATA ACROSS SPECIES PROBLEMATIC. IN THIS PROPOSAL, DIVYA IS PLANNING TO DEVELOP NOVEL 2-DIMENSIONAL AND 3-DIMENSIONAL HUMAN CELL-BASED MODELS OF THE CORNEAL STROMA FOR USE IN WOUND HEALING STUDIES. TO BETTER MIMIC THE NATIVE CORNEA STROMAL STRUCTURE, SHE WILL BE GROWING A HUMAN CORNEAL KERATOCYTE CELL LINE ON MICROPATTERNS OF ALIGNED COLLAGEN FIBRILS, AS THE GEOMETRY AND TOPOGRAPHY OF THE CELL MICROENVIRONMENT MODULATE CORNEAL CELL BEHAVIOR. SHE WILL THEN DEVELOP A WOUND HEALING ASSAY IN THIS SYSTEM TO REDUCE THE USE OF ANIMALS FOR THIS PURPOSE. TEXAS A&amp;M UNIVERSITY (TEXAS): THE GRANT WAS GIVEN TO TEXAS A&amp;M UNIVERSITY TO SUPPORT THE RESEARCH CONDUCTED BY JASON EADES. MR. EADES' RESEARCH FOCUSES UPON "REPLACING ANIMAL MODELS OF THROMBOSIS WITH VEIN-CHIP: A CASE STUDY EVALUATING SARS-COV-2-INDUCED THROMBOSIS AND MECHANICAL THERAPEUTICS." THE GOAL OF THIS RESEARCH FOLLOWS THE OBSERVATION THAT DURING THE COVID-19 PANDEMIC, SOME INDIVIDUALS INFECTED WITH CORONAVIRUS DEVELOPED BLOOD CLOTTING CONDITIONS LIKE DEEP VEIN THROMBOSIS, BUT THE MECHANISM FOR HOW THIS OCCURS REMAINS UNKNOWN. IN THIS PROPOSAL, MR. EADES PLANS TO USE THE VEIN CHIP DEVELOPED IN HIS LAB AS A PRECLINICAL NONANIMAL MODEL TO BETTER UNDERSTAND THIS PROCESS. ANIMAL MODELS LACK THE CELL SURFACE RECEPTORS IMPORTANT FOR ATTACHMENT AND INVASION OF THE CORONAVIRUS. HIS LAB HAS DEVELOPED A VEIN CHIP MODEL IN WHICH BLOOD VESSEL CELLS CAN BE CULTURED WITH PROTEINS THEY WOULD NORMALLY INTERACT WITH IN THE BODY. FLUIDS, LIKE PATIENT BLOOD, CAN BE CIRCULATED THROUGH THE DEVICE AT DIFFERENT FLOW RATES TO MIMIC NORMAL AND PATHOLOGICAL CONDITIONS. MR. EADES WILL INTRODUCE AN INACTIVATED VERSION OF THE VIRUS, AS WELL AS STRUCTURAL PROTEINS OF THE VIRUS, AND CYTOKINES NORMALLY FOUND WITH VIRUS INFECTION, TO THE VEIN CHIP AND WILL USE PROTEOMIC AND TRANSCRIPTOMIC APPROACHES TO BETTER UNDERSTAND THE IMPACT OF THE VIRUS ON BLOOD VESSEL CELLS AND BLOOD CLOT FORMATION. HE WILL ALSO USE THE DEVICE TO STUDY THE IMPACT OF COMPRESSION THERAPY FOR THROMBOSIS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="RetDoc1042400001">
      <SeverancePaymentInd>0</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>0</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>0</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>0</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>0</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>0</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>0</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>0</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>0</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>KENNETH KANDARAS</PersonNm>
        <TitleTxt>PRESIDENT</TitleTxt>
        <BaseCompensationFilingOrgAmt>0</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>166156</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>0</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>0</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>166156</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
    </IRS990ScheduleJ>
    <IRS990ScheduleL documentId="RetDoc1042800001">
      <BusTrInvolveInterestedPrsnGrp>
        <NameOfInterested>
          <PersonNm>KENNETH CUNNIFF</PersonNm>
        </NameOfInterested>
        <RelationshipDescriptionTxt>SPOUSE OF BOARD MEMBER</RelationshipDescriptionTxt>
        <TransactionAmt>18000</TransactionAmt>
        <TransactionDesc>LEGAL COUNSEL AND PROGRAM COORDINATING FOR THE ORGANIZATION</TransactionDesc>
        <SharingOfRevenuesInd>0</SharingOfRevenuesInd>
      </BusTrInvolveInterestedPrsnGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE L PART IV</FormAndLineReferenceDesc>
        <ExplanationTxt>KENNETH CUNNIFF'S COMPENSATION IS DETERMINED BY THE BOARD WITHOUT MARY MARGARET CUNNIFF'S INVOLVEMENT OR VOTE.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleL>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 11B</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PRESIDENT OF THE IFER PRESENTS THE FORM 990 TO THE BOARD OF DIRECTORS FOR THEIR REVIEW PRIOR TO SIGNING AND FILING THE RETURN.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 12C</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PRESIDENT AND LEGAL COUNSEL MAINTAIN ONGOING COMMUNICATION WITH BOARD MEMBERS TO LEARN THEIR ACTIVITIES AND POTENTIAL CONFLICTS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 19</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FORM 990, AND ALL OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON THEIR REQUEST. THE FORM 990 FOR THE CURRENT YEAR AND FOR PRIOR YEARS ARE AVAILABLE ON THE WEBSITE IRS.GOV.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XII, LINE 2C:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PROCESS HAS NOT CHANGED FROM PRIOR YEARS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
    <IRS990ScheduleR documentId="RetDoc1043400001">
      <IdRelatedTaxExemptOrgGrp>
        <DisregardedEntityName>
          <BusinessNameLine1Txt>NATIONAL ANTI-VIVISECTION SOCIETY</BusinessNameLine1Txt>
        </DisregardedEntityName>
        <USAddress>
          <AddressLine1Txt>444 N WELLS ST STE 406</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60654</ZIPCd>
        </USAddress>
        <EIN>362229588</EIN>
        <PrimaryActivitiesTxt>ENDING THE EXPLOITATION OF ANIMALS USED IN SCIENCE</PrimaryActivitiesTxt>
        <LegalDomicileStateCd>IL</LegalDomicileStateCd>
        <ExemptCodeSectionTxt>501(C)(3)</ExemptCodeSectionTxt>
        <PublicCharityStatusTxt>LINE 7</PublicCharityStatusTxt>
        <ControlledOrganizationInd>0</ControlledOrganizationInd>
      </IdRelatedTaxExemptOrgGrp>
      <ReceiptOfIntAnntsRntsRyltsInd>0</ReceiptOfIntAnntsRntsRyltsInd>
      <GiftGrntOrCapContriToOthOrgInd>0</GiftGrntOrCapContriToOthOrgInd>
      <GiftGrntCapContriFromOthOrgInd>1</GiftGrntCapContriFromOthOrgInd>
      <LoansOrGuaranteesToOtherOrgInd>0</LoansOrGuaranteesToOtherOrgInd>
      <LoansOrGuaranteesFromOthOrgInd>0</LoansOrGuaranteesFromOthOrgInd>
      <DivRelatedOrganizationInd>0</DivRelatedOrganizationInd>
      <AssetSaleToOtherOrgInd>0</AssetSaleToOtherOrgInd>
      <AssetPurchaseFromOtherOrgInd>0</AssetPurchaseFromOtherOrgInd>
      <AssetExchangeInd>0</AssetExchangeInd>
      <RentalOfFacilitiesToOthOrgInd>0</RentalOfFacilitiesToOthOrgInd>
      <RentalOfFcltsFromOthOrgInd>0</RentalOfFcltsFromOthOrgInd>
      <PerformOfServicesForOthOrgInd>0</PerformOfServicesForOthOrgInd>
      <PerformOfServicesByOtherOrgInd>1</PerformOfServicesByOtherOrgInd>
      <SharingOfFacilitiesInd>0</SharingOfFacilitiesInd>
      <PaidEmployeesSharingInd>0</PaidEmployeesSharingInd>
      <ReimbursementPaidToOtherOrgInd>0</ReimbursementPaidToOtherOrgInd>
      <ReimbursementPaidByOtherOrgInd>0</ReimbursementPaidByOtherOrgInd>
      <TransferToOtherOrgInd>0</TransferToOtherOrgInd>
      <TransferFromOtherOrgInd>0</TransferFromOtherOrgInd>
      <TransactionsRelatedOrgGrp>
        <OtherOrganizationName>
          <BusinessNameLine1Txt>NATIONAL ANTI-VIVISECTION SOCIETY</BusinessNameLine1Txt>
        </OtherOrganizationName>
        <TransactionTypeTxt>C</TransactionTypeTxt>
        <InvolvedAmt>200000</InvolvedAmt>
        <MethodOfAmountDeterminationTxt>FAIR VALUE - CASH</MethodOfAmountDeterminationTxt>
      </TransactionsRelatedOrgGrp>
      <TransactionsRelatedOrgGrp>
        <OtherOrganizationName>
          <BusinessNameLine1Txt>NATIONAL ANTI-VIVISECTION SOCIETY</BusinessNameLine1Txt>
        </OtherOrganizationName>
        <TransactionTypeTxt>M</TransactionTypeTxt>
        <InvolvedAmt>57040</InvolvedAmt>
        <MethodOfAmountDeterminationTxt>FAIR MARKET VALUE</MethodOfAmountDeterminationTxt>
      </TransactionsRelatedOrgGrp>
    </IRS990ScheduleR>
  </ReturnData>
</Return>